Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash & Equivalents (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash & Equivalents for 4 consecutive years, with $127.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents changed N/A to $127.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $127.0 million, a N/A change, with the full-year FY2024 number at $58.4 million, up 23.49% from a year prior.
  • Cash & Equivalents was $127.0 million for Q3 2025 at Century Therapeutics, down from $152.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $180.1 million in Q1 2025 to a low of $41.5 million in Q2 2024.
  • A 4-year average of $95.3 million and a median of $97.8 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 50.33% in 2023, then surged 284.75% in 2025.
  • Century Therapeutics' Cash & Equivalents stood at $84.3 million in 2022, then plummeted by 43.84% to $47.3 million in 2023, then increased by 23.49% to $58.4 million in 2024, then surged by 117.26% to $127.0 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Cash & Equivalents are $127.0 million (Q3 2025), $152.3 million (Q2 2025), and $180.1 million (Q1 2025).